Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Hanneke van Santen

Pediatric Endocrinologist, Associate Professor

Endocrine effects of cancer treatment, pediatric thyroid cancer and pediatric craniopharyngioma

Dr. HM van Santen, associate professor, moved her career in 2013 to Utrecht to support the Máxima initiative and to coordinate the endocrine care for children with cancer in the Princess Máxima Center.

She has co-authored  > 100 publications on the endocrine effects of childhood cancer treatment, of which many as first or senior author.

She is an associate professor and Clinical Scientist in the research program of Child Health, WKZ, UMCU and associate group leader in the Princess Máxima Center for Pediatric Oncology. She collaborates closely with many research groups, both in the Maxima (Tissing group/supportive care, Kremer group/ Late Effects, Partanen group/neuro-cognitive) and in the UMCU ( Rare Endocrine Tumors/ Prof G Valk). Internationally, she collaborates a.o. with the endocrine and late effects department of the St Jude’s Hospital (Dr W Chemaitilly, Dr M Hudson, Dt T Merchant), Sick Kids Hospital Toronto and the International Guideline Harmonization Group https://www.ighg.org/

Her research program focusses on the endocrine effects of childhood cancer treatment, with special interest for the thyroid gland, pituitary gland and hypothalamus aiming to preserve an intact endocrine system in children with cancer enabling normal growth and development of the child during and after childhood cancer treatment.

She is chair of the Late Effects of Childhood Cancer International Guideline Harmonization Groups (IGHG) for thyroid and hypothalamic-pituitary disorders, and member of the IGHG working groups for male and female gonadal toxicity and preservation of fertility and metabolic syndrome.

She is chair of the Dutch and the European Guideline for Thyroid cancer in children and the coordinator of the NFU/ ENDO-ERN expertise center Thyroid Tumors in Utrecht as well as the NFU endorsed center for rare Hypothalamic disease ( including pituitary tumors and craniopharyngioma).

She is chair of the SIOPe craniopharyngioma working group, and of the local M4C Craniopharyngioma.

For the Dutch Endocrinologists, Hanneke is chair of the “Sectie Kinderendocrinologie/ NvK”.

In addition, she is member of the the SIOP supportive care group, the SIOP low grade glioma working group, the Dutch Growth Hormone Advisory board and has a consultative function for the “Cyberpoli” for thyroid diseases and craniopharyngioma.



  • The development of fatigue after treatment for pediatric brain tumors does not differ between tumor locations

    • mei 2024
    • Elin, Irestorm, et al
    • Pediatric Blood and Cancer
  • A 14-year-old girl with premature ovarian insufficiency but with a positive pregnancy test

    • apr. 2024
    • Robbert N H, Touwslager, et al
    • Journal of Pediatric Endocrinology and Metabolism
  • Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

    • okt. 2023
    • Evelien, de Vos-Kerkhof, et al
    • Frontiers in endocrinology
  • Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer

    • jan. 2023
    • Stephanie, van der Leij, et al
    • Critical Reviews in Oncology/Hematology
  • Questionnaire- and linkage-based outcomes in Dutch childhood cancer survivors

    • jan. 2023
    • , et al
    • Cancer Medicine
View all publications